Kymera Therapeutics, Inc. — Director's Dealing 2021

Nov 23, 2021

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Kymera Therapeutics, Inc. (KYMR)
CIK: 0001815442
Period of Report: 2021-11-23

Reporting Person: Jacobs Bruce N. (Chief Financial Officer)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2021-11-23	Common Stock	M	10000	$2.08	Acquired	17256	Direct

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2021-11-23	Stock Option (Right to Buy)	$2.08	M	10000	Disposed	2029-08-28	Common Stock (10000)	Direct

Footnotes

F1: Twenty-five percent (25%) of the shares underlying this stock option vested on July 1, 2020 and the remaining shares shall vest in equal monthly installments over the remaining thirty-six (36) months, subject to the reporting person's continued employment through each vesting date.